Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Surrozen, Inc.NASDAQ: SRZN
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $65K fell 77.9% year over year, behind the -77.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 44.4% from the prior quarter. Over 3 fiscal years it compounded at -35.0% a year.
Context
- Depreciation & amortization amounted to 15.4% of revenue in FY2025, up 1.9 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -77.9% toward the trailing-twelve-month pace of -77.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 537K USD
- Year-over-year change
- -62.8%
- 4-year CAGR
- -36.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 537K | -62.8% |
| FY2024 | 2024-12-31 | 1.44M | -24.5% |
| FY2023 | 2023-12-31 | 1.91M | -2.3% |
| FY2022 | 2022-12-31 | 1.96M | -40.7% |
| FY2021 | 2021-12-31 | 3.3M | — |
Depreciation & Amortization vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 depreciation & amortization of $308K is the 4th highest of the 8 companies compared; the peer median is $291K.
- Its year-over-year change of -77.1% is the 7th highest of 8, against a peer median of -3.9%.
- Depreciation & amortization amounts to 4.1% of revenue for SRZN, versus a peer median of 6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M | -44.0% | +12.9% | 6.0% | |
| LTM Mar 2026 | $6.03M | -3.9% | +1.1% | 40.1% | |
| LTM Mar 2026 | $398.22K | +164.2% | +454.8% | — | |
| LTM Mar 2026 | $308K | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $291K | -90.7% | -55.3% | — | |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +241.9% | +136.6% | 0.4% |
| LTM Mar 2026 | $876 | -75.7% | -21.0% | — | |
| Peer median (excluding SRZN) | $291K | -3.9% | +1.1% | 6.0% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.5M | 0 | 10.66M | 3.48M |
| Cost of Revenue | 3.3M | 3.27M | 27.23M | 0 | 537K |
| Gross Profit | (3.3M) | 9.23M | (27.23M) | 10.66M | 2.94M |
| Gross Margin | — | 73.8% | — | 100.0% | 84.6% |
| Research & Development | 36.88M | 37.01M | 27.23M | 21.13M | 29.37M |
| Selling, General & Admin | 14.21M | 19.83M | 15.8M | 15.06M | 16.2M |
| Operating Expenses | 51.09M | 53.57M | 18.55M | 36.19M | 45.03M |
| Depreciation & Amortization | 3.3M | 1.96M | 1.91M | 1.44M | 537K |
| EBITDA | (51.35M) | (34.05M) | (41.13M) | (62.12M) | (241.49M) |
| EBITDA Margin | — | -272.4% | — | -583.0% | -6945.3% |
| Operating Income | (54.39M) | (44.34M) | (45.78M) | (25.54M) | (42.09M) |
| Operating Margin | — | -354.7% | — | -239.7% | -1210.6% |
| Interest Income | 72K | 781K | 2.34M | 1.69M | 3.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (257K) | 8.34M | 2.74M | (38.03M) | (199.93M) |
| Income Before Tax | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Pre-Tax Margin | — | -288.0% | — | -596.6% | -6960.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.51M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Net Margin | — | -288.0% | — | -596.6% | -6960.8% |
| EPS (Basic) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| EPS (Diluted) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| Weighted Avg Shares | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
| Weighted Avg Shares (Diluted) | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.